Assignee
NEURIMMUNE HOLDING AG
CH·16 granted patents·9 pending applications·24 citations·filing 2013–2025
Top patents by PatentIndex Score
25 records- 0189US11180545B2Antibody-based therapy of transthyretin (TTR) amyloidosis and human-derived antibodies thereforNEURIMMUNE HOLDING AG·Filed 2019·Granted Nov 23, 2021·3 cites·21 claims
- 0287US10961322B2Human-derived anti-dipeptide repeats (DPRs) antibodyNEURIMMUNE HOLDING AG·Filed 2019·Granted Mar 30, 2021·2 cites·27 claims
- 0385US2024254256A1Human Anti-SOD1 AntibodiesNEURIMMUNE HOLDING AG·Filed 2024·Application pending·0 cites
- 0483US10344080B2Antibody-based therapy of transthyretin (TTR) amyloidosis and human-derived antibodies thereforNEURIMMUNE HOLDING AG·Filed 2014·Granted Jul 9, 2019·6 cites·22 claims
- 0582US11401325B2Human-derived anti-huntingtin (HTT) antibodies and uses thereofNEURIMMUNE HOLDING AG·Filed 2020·Granted Aug 2, 2022·1 cites·12 claims
- 0682US2024279361A1Human-derived anti-dipeptide repeats (dprs) antibodyNEURIMMUNE HOLDING AG·Filed 2023·Application pending·0 cites
- 0778US10882902B2Human islet amyloid polypeptide (hIAPP) specific antibodies and uses thereofNEURIMMUNE HOLDING AG·Filed 2018·Granted Jan 5, 2021·1 cites·16 claims
- 0878US10556946B2Human derived anti-Huntingtin (HTT) antibodies and uses thereofNEURIMMUNE HOLDING AG·Filed 2015·Granted Feb 11, 2020·2 cites·15 claims
- 0978US10392447B2Human-derived anti-dipeptide repeats (DPRs) antibodyNEURIMMUNE HOLDING AG·Filed 2015·Granted Aug 27, 2019·2 cites·120 claims
- 1077US2022267471A1Human Anti-SOD1 AntibodiesNEURIMMUNE HOLDING AG·Filed 2022·Application pending·0 cites
- 1175US12234281B2Antibody-based therapy of transthyretin (TTR) amyloidosis and human-derived antibodies thereforNEURIMMUNE HOLDING AG·Filed 2021·Granted Feb 25, 2025·0 cites·13 claims
- 1275US10450365B2Recombinant human antibodies for therapy and prevention of polyomavirus-related diseasesNEURIMMUNE HOLDING AG·Filed 2017·Granted Oct 22, 2019·2 cites·21 claims
- 1373US9771413B2Recombinant human antibodies for therapy and prevention of polyomavirus-related diseasesNEURIMMUNE HOLDING AG·Filed 2014·Granted Sep 26, 2017·2 cites·32 claims
- 1473US2022332808A1Human-derived anti-huntingtin (htt) antibodies and uses thereofNEURIMMUNE HOLDING AG·Filed 2022·Application pending·0 cites
- 1571US11352441B2Human anti-SOD1 antibodiesNEURIMMUNE HOLDING AG·Filed 2019·Granted Jun 7, 2022·0 cites·14 claims
- 1671US10344097B2Human anti-SOD1 antibodiesNEURIMMUNE HOLDING AG·Filed 2016·Granted Jul 9, 2019·1 cites·11 claims
- 1771US10072074B2Human islet amyloid polypeptide (HIAPP) specific antibodies and uses thereofNEURIMMUNE HOLDING AG·Filed 2016·Granted Sep 11, 2018·1 cites·26 claims
- 1871US2025145699A1Antibody-based therapy of transthyretin (ttr) amyloidosis and human-derived antibodies thereforNEURIMMUNE HOLDING AG·Filed 2025·Application pending·0 cites
- 1971US2025154235A1Antibody-based therapy of transthyretin (ttr) amyloidosis and human-derived antibodies thereforNEURIMMUNE HOLDING AG·Filed 2025·Application pending·0 cites
- 2069US9475866B2Human islet amyloid polypeptide (hIAPP) specific antibodies and uses thereofNEURIMMUNE HOLDING AG·Filed 2013·Granted Oct 25, 2016·1 cites·22 claims
- 2169US2023287106A1Novel compounds capable of antagonizing islet amyloid polypeptide (iapp) induced beta-cell damage and impaired glucose toleranceNEURIMMUNE HOLDING AG·Filed 2022·Application pending·0 cites
- 2267US2021107972A1Human islet amyloid polypeptide (hiapp) specific antibodies and uses thereofNEURIMMUNE HOLDING AG·Filed 2020·Application pending·0 cites
- 2362US11608372B2Recombinant human antibodies for therapy and prevention of polyomavirus-related diseasesNEURIMMUNE HOLDING AG·Filed 2019·Granted Mar 21, 2023·0 cites·24 claims
- 2460US2020231667A1Novel compounds capable of antagonizing islet amyloid polypeptide (iapp) induced beta-cell damage and impaired glucose toleranceNEURIMMUNE HOLDING AG·Filed 2019·Application pending·0 cites
- 2552US10544213B2Compounds capable of antagonizing islet amyloid polypeptide (IAPP) induced beta-cell damage and impaired glucose toleranceNEURIMMUNE HOLDING AG·Filed 2015·Granted Jan 28, 2020·0 cites·24 claims
Join the waitlist — get patent alerts
Get an alert when NEURIMMUNE HOLDING AG files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →